Agilent Technologies Inc. (NYSE: A) today announced it has awarded a grant to the newly established Duke Molecular Physiology Institute. The DMPI research team is using Agilent’s integrated biology solutions to gain new insights into the metabolic and physiologic aspects of major chronic diseases such as cardiovascular disease. DMPI is headed by Dr. Christopher Newgard, professor at Duke University School of Medicine’s Department of Pharmacology and Cancer Biology and director of the Sarah W. Stedman Nutrition and Metabolism Center and the Institute for Molecular Physiology. “The Duke Molecular Physiology Institute seeks to combine strong genomics, epigenomics, transcriptomics and metabolomics platforms with computational biology, clinical translation and basic science expertise to gain new insights into the mechanisms of cardiometabolic diseases,” said Dr. Newgard. “We thank Agilent for supporting our research and look forward to collaborating to advance the understanding of cardiovascular and undiagnosed metabolic diseases.” Dr. Newgard’s pathway-centric research is powered by Agilent’s GC/MS, triple quadrupole LC/MS and quadrupole time-of-flight LC/MS systems along with software such as MassHunter Workstation with ChemStation in association with the Agilent-Fiehn GC/MS Metabolomics RTL Library and MassHunter Qualitative Software using METLIN Personal Metabolite Database and Library. Agilent’s GeneSpring GX software, Mass Profiler Pro and Pathway Architect will provide critical capabilities in data integration and pathway directed interpretation. “We are pleased to support Dr. Newgard and his team at Duke for their pioneering translational research,” said Steve Fischer, Agilent’s director of ‘Omics Applications, who is working closely with the team. “They will use the power of integrating different ‘omics data to better understand complex disease mechanisms and map out previously unknown pathways to disease phenotypes. This should accelerate their understanding of complicated processes in cardiometabolic diseases and lead to the faster development of treatments.”
“We are strong proponents of applying an integrated approach to solving important health problems such as cardiometabolic disease,” added Leo Bonilla, Agilent’s director of Integrated Biology. “We look forward to following Dr. Newgard’s pioneering research at Duke.”About Agilent Technologies University Relations Agilent takes an active role in supporting higher education and research around the world. To learn more about the latest research collaborations, research tools, education support, recruiting of top university talent and philanthropy, visit: Agilent University Relations. About Agilent’s Integrated Biology Solutions Agilent Technologies provides researchers with analytical products that span all four major “omics” disciplines. These combined hardware/software and informatics solutions are fueling the next generation of pathway-centric multi-omics research and yielding valuable information about drug responses, drug resistance, diagnostic markers, and fundamental disease/toxicity pathways. For more information about Agilent’s complete portfolio of integrated biology solutions, visit http://biology.chem.agilent.com. About Agilent Technologies Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company’s 20,600 employees serve customers in more than 100 countries. Agilent had revenues of $6.8 billion in fiscal 2013. Information about Agilent is available at www.agilent.com. On Sept. 19, 2013, Agilent announced plans to separate into two publicly traded companies through a tax-free spinoff of its electronic measurement business. The new company is named Keysight Technologies, Inc. The separation is expected to be completed in early November 2014. NOTE TO EDITORS: Further technology, corporate citizenship and executive news is available at www.agilent.com/go/news.